Search

The article presents findings of a clinical trial on the therapeutic use of rosiglitazone in reducing diagnosed type 2 diabetes among patients with impaired fasting glucose tolerance. The design of the clinical trial is described. The incidence of the primary composite endpoint of diabetes or death between the ramipril and placebo groups is assessed. The effect of ramipril on the proportion of individuals who returned to normoglycaemia is considered.

Provides information on the therapeutic use of rimonabant in improving glycaemic control and other diabetes-associated risk factors in obese or overweight patients with type 2 diabetes mellitus. Details of pivotal phases of clinical trials included in the Rimonabant In Obesity (RIO) program; Benefits from other RIO-DIABETES trials; Baseline prevalence of risk-factors and use of antidiabetic treatments in the program; Effects of bodyweight and waist circumference on the treatment.

Intravenous ibandronic acid [ibandronate] administered once every 2 or 3 months is at least as effective as daily oral ibandronic acid in terms of improvements in bone mineral density (BMD) in women with postmenopausal osteoporosis, according to 1-year results from the ongoing DIVA study presented at The Endocrine Society's 87th Annual Meeting (ENDO 2005) [San Diego, California, US, June 2005]. Both the 2-monthly and 3-monthly IV regimens were as well tolerated as the currently established daily oral ibandronic acid regimen and demonstrated similar safety profiles. In addition, efficacy and tolerability data on once-monthly oral ibandronic acid from the MOBILE study were presented in posters, showing efficacy at least equivalent to that of the daily oral regimen, again with a similar safety and tolerability profile. These alternatives to current oral bisphosphonate regimens may therefore present advantages for some women in terms of treatment tolerance and compliance. [ABSTRACT FROM AUTHOR]

Reports on the first clinical trial of statins in patients with multiple sclerosis. Percentage of reduction in the mean number of gadolinium-enhancing lesions; Potential of statins in multiple sclerosis therapy.